Why Novavax Was a Coronavirus Stock Winner After Hours Today | The Motley Fool

Why Novavax Was a Coronavirus Stock Winner After Hours Today | The Motley Fool
Spread the love

What happened

Coronavirus vaccine developer Novavax‘s (NASDAQ:NVAX) stock blasted more than 30% higher in after-market trading on Thursday in reaction to good news about its vaccine candidate.

So what

Novavax announced after market hours that its NVx-CoV2373 met its primary endpoint and demonstrated over 89% efficacy in a phase 3 clinical trial in the U.K. Severe, serious, and medically attended adverse events were at low levels.

The biotech also reported encouraging results for a phase 2b study undertaken in South Africa, although the efficacy was lower (60% in the case of HIV-negative participants, who comprised 94% of the study).

Patient receiving a vaccination shot.

Image source: Getty Images.

Crucially, “NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but…



Original Author

Please follow and like us:
editor

editor

Live Updates COVID-19 CASES
RSS
Follow by Email